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Abstract The binding of peptides to classical major histo-
compatibility complex (MHC) class I proteins is the single
most selective step in antigen presentation. However, the
peptide-binding specificity of cattle MHC (bovine leucocyte
antigen, BoLA) class I (BoLA-I) molecules remains poorly
characterized. Here, we demonstrate how a combination of
high-throughput assays using positional scanning combinato-
rial peptide libraries, peptide dissociation, and peptide-
binding affinity binding measurements can be combined with
bioinformatics to effectively characterize the functionality of
BoLA-I molecules. Using this strategy, we characterized eight
BoLA-I molecules, and found the peptide specificity to
resemble that of human MHC-I molecules with primary an-
chors most often at P2 and P9, and occasional auxiliary P1/P3/
P5/P6 anchors. We analyzed nine reported CTL epitopes from
Theileria parva, and in eight cases, stable and high affinity
binding was confirmed. A set of peptides were tested for
binding affinity to the eight BoLA proteins and used to refine
the predictors of peptide–MHC binding NetMHC and
NetMHCpan. The inclusion of BoLA-specific peptide-bind-
ing data led to a significant improvement in prediction accu-
racy for reported T. parva CTL epitopes. For reported CTL
epitopes with weak or no predicted binding, these refined
prediction methods suggested presence of nested minimal
epitopes with high-predicted binding affinity. The enhanced
affinity of the alternative peptides was in all cases confirmed
experimentally. This study demonstrates how biochemical
high-throughput assays combined with immunoinformatics
can be used to characterize the peptide-binding motifs of
BoLA-I molecules, boosting performance of MHC peptide-
binding prediction methods, and empowering rational epitope
discovery in cattle.
Keywords Bovine leucocyte antigen . BoLA . Rational
epitope discovery . CTL epitopes . Immunoinformatics
Introduction
Intracellular proteins are displayed for CD8+ T cells to survey
as peptide fragments on the surface of all nucleated cells in the
context of MHC-I molecules. The binding of peptides to
MHC-I proteins is the most selective event in antigen presen-
tation to CD8 T cells and stable interaction of the peptide–
MHC complex is a prerequisite for effective surface presen-
tation (Yewdell and Bennink 1999). This process has evolved
to allow T cell surveillance of the intracellular environment of
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cells resulting in a critical aspect of the immune response to
infection and oncogenesis.
The tick-borne parasite Theileria parva causes the deadly
cattle disease East Coast fever (ECF) in cattle, which is of
significant economic importance and a great threat to small-
holder farmers in sub-Saharan Africa. Annually, about 1 mil-
lion cattle die from ECF. Recently, it has been demonstrated
that immunity against T. parva is dominated by a strong CD8+
T cell response that kills parasite infected lymphocytes
(McKeever et al. 1994). We have previously proposed a
reverse immunology strategy for effective and rational epitope
discovery based on in silico prediction tools combined with
experimental peptide-binding data from recombinant bovine
MHCs (Nene et al. 2012). Our aim here is to extend this
approach and improve the performance of the MHC peptide-
binding predictionmethodsNetMHC (Lundegaard et al. 2008;
Nielsen et al. 2003) and NetMHCpan (Hoof et al. 2009;
Nielsen et al. 2007) by integrating peptide-binding affinity
data for a limited set of BoLA-I (bovine leucocyte antigen)
MHC class I molecules known to restrict T. parva CTL
epitopes (Graham et al. 2006) and/or prevalent in breeds
available to us (Codner et al. 2012). This will demonstrate
how such an approach in a highly cost-effective manner can
be used to guide the search for CTL epitopes in cattle.
Cattle have at least six MHC class I genes (Holmes et al.
2003). In each individual, only a subset of one to three loci are
transcribed leading to a large set of variable haplotype com-
binations (Birch et al. 2006). Previous studies on peptide
binding to cattle MHCs have mostly been small-scale using
alanine scans and/or X-ray crystallography of one or two
individual peptide sequences (De Groot et al. 2003; Hegde
et al. 1999; Li et al. 2011; Macdonald et al. 2010;
Sinnathamby et al. 2004), or pool sequencing of peptides
eluted from bovine cells (Gaddum et al. 1996; Hegde et al.
1995) to characterize BoLA-I binding motifs.
Given this limited set of data, the performance of methods
for predicting peptide binding to BoLA class I molecules
remains suboptimal. In order to improve such methods and
generate experimental peptide-binding data, we expressed
recombinant bovine MHC class I proteins (BoLA-I) and de-
termined their peptide-binding specificity. Our strategy was to
use a nonameric Positional Scanning Combinatorial Peptide
Library (PSCPL) in combination with a high-throughput pep-
tide–MHC-I dissociation assay (Harndahl et al. 2011), and
feed this data into peptide-binding prediction methods. We
have earlier described how this approach can be used to
characterize binding specificities of human MHC class I mol-
ecules (paper submitted for publication).We used the resulting
data to identify discrete peptides from our peptide repository,
which contains more than 9,000 different nonameric synthetic
peptides. In parallel, we used the NetMHCpan method, prior
to inclusion of BoLA binding data, to identify peptides from
the same peptide repository that matches the predicted binding
motif but did not match the PSCPL data. These individual
experimental bovine peptide-binding data allowed us to con-
struct refined versions of NetMHC and NetMHCpan. These
methods demonstrated a significantly improved performance
for prediction of known bovine CD8 T cell epitopes, leading
to more accurate predictions of possible T cell epitopes from
genomic data.
The work presented here is, to the best of our knowledge,
the first study that provides detailed peptide-binding motifs
and quantitative binding data for bovineMHC class I proteins.
The resulting updated versions of NetMHCpan (version 2.8)
and NetMHC (version 3.4) enable more reliable prediction of
peptide binding to BoLA-I molecule and are publicly avail-
able via the CBS servers (www.cbs.dtu.dk/services).
Materials and methods
Peptides and peptide libraries
All peptides, except the known T. parva epitopes described
below, were purchased from Schafer-N Copenhagen,
Denmark. Briefly, peptides were synthesized using standard
9-fluorenylmethyloxycarbonyl (Fmoc) chemistry. The synthe-
sized peptides were purified by reversed-phase high perfor-
mance liquid chromatography (to at least >80 % purity fre-
quently 95–99 %), validated by mass spectrometry and quan-
titated by weight. Peptides for the known T. parva CD8 T cell
epitopes were purchased from Mimotopes (Victoria,
Australia) purity=95 %. PSCPL peptides were synthesized
using standard solid-phase Fmoc chemistry on 2-chlorotrityl
chloride resins. Briefly, an equimolar mixture of 19 of the
common Fmoc amino acids (excluding cysteine) was pre-
pared for each synthesis and used for coupling in 8 positions,
whereas a single type of Fmoc amino acid (including cysteine)
was used in one position. This position was changed in each
synthesis starting with the N-terminus and ending with the C
terminus. In one synthesis, the amino acid pool was used in all
nine positions. The library therefore consisted of 20×9+1=
181 individual peptide libraries.
& Twenty PSCPL sub-libraries describing position 1: AX8,
CX8, DX8, ….YX8
& Twenty PSCPL sub-libraries describing position 2: XAX7,
XCX7, XDX7, …. XYX7
& Etc.
& Twenty PSCPL sub-libraries describing position 9: X8A,
X8C, X8D, …. X8Y
& A completely random peptide library: X9
X denotes the random incorporation of the amino acids
from the mixture, whereas the single letter amino acid abbre-
viation is used to denote identity of the fixed amino acid.
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The peptides in each synthesis were cleaved from the resin
in trifluoroacetic acid–1,2-ethanedithiol–triisopropylsilane–
water 95:2:1:3v/v/v/v, precipitated in cold diethyl ether, and
extracted with water before desalting on C18-columns freeze
drying and weighing.
Cloning, expression, and purification of biotinylated bovine
MHC class I proteins
The recombinant biotinylated bovine MHC proteins were
expressed the same way as recombinant human MHCs as
previously described (Leisner et al. 2008; Ostergaard
Pedersen et al. 2001). In short, the desired MHC sequence
(residues 1–275) was back-translated and cloned into the
IPTG inducible pET28a expression vector containing a biotin
signal peptide (BSP) and a histidine affinity tag (HAT). The
recombinant constructs were validated by DNA sequencing
and transformed into the Escherichia coli strain BL21(DE3)
previously transformed with the pACYC (Avidity, Denver)
vector containing the BirA gene encoding biotin ligase. The
transformed cells were grown in a 2-L fermentor (LabFors®),
in media supplemented with kanamycin (50 μg/ml) and chlor-
amphenicol (20 μg/ml) to maintain the pET28a derived ex-
pression plasmid and the BirA containing pACYC184 plas-
mid, respectively. When the culture reached an optical density
of OD600=25 the media was supplemented with biotin (sigma
#B4501, final concentration 125 μg/ml), and IPTG (1 mM)
was added to induce expression of the MHC-I heavy chain
gene and of the BirA gene; the induced culture was continued
for 3 h. At the end of induction, protease inhibitor (PMSF
80μg/L) was added and the cells were lysed in a cell-disrupter
(basic Z, constant systems Ltd Daventry, UK) set at 2,300 bar.
The released inclusion bodies containing biotinylated MHC-I
heavy chain proteins were harvested by centrifugation
(Sorwall RC6, 20 min, 17,000g).
The inclusion bodies were washed in PBS, 0.5 % NP-40
(Sigma), 0.1 % deoxycholic acid (DOC, Sigma) and dissolved
at 4 °C overnight in 8 M urea-Tris buffer (8 M urea, 25 mM
Tris pH 8) using 200 ml per 100 g wet cell paste, and cleared
by centrifugation. The dissolved MHC-I proteins were then
purified using Ni2+/IDAmetal chelating affinity column chro-
matography, Hydrophobic ionic chromatography (phenyl se-
pharose high performance) and eventually by Superdex200
gel filtration column chromatography, driven by a Fast Protein
Liquid Chromatography machine (P920 Amersham Biotech
industries). Peak fractions were identified by A280 absor-
bance, SDS-PAGE analysis and pooled. Throughout purifica-
tion theMHC proteins were dissolved in 8MUrea tomaintain
denaturing conditions. At no time the MHCs were exposed to
reducing conditions, which ensures purification of highly
active pre-oxidized moieties as previously described
(Ostergaard Pedersen et al. 2001). Protein concentrations were
determined by BCA assay (Thermo Scientific Pierce®). The
degree of biotinylation (usually >95 %) were determined by a
gel-shift assay (Leisner et al. 2008) and the pre-oxidized,
denatured proteins were stored at −24 °C until use.
Production of recombinant human β2m
Recombinant β2m was produced by overexpression in E. coli,
refolded and purified as previously described (Ferre et al.
2005).
Production of recombinant bovine β2m
Recombinant bovine β2m was expressed in E. coli as de-
scribed for the bovine MHC-I heavy chain. Inclusion bodies
containing recombinant bovine β2m were dissolved in 8 M
urea and purified by anion exchange chromatography (Q
Sepharose Fast Flow, QSFF, Ge Healthcare Life Sciences
17-0510-01) under denaturing conditions. The protein was
refolded overnight by drop-wise dilution into 25 mM Tris,
300 mM urea, pH 8, and concentrated by tangential flow
ultrafiltration (Vivaflow). The concentrated product was
buffer-exchanged into PBS by gel filtration (Superdex 200,
Amersham Biosciences) and concentrated. As a result of
E. coli expression, the recombinant bovine β2m protein in-
cludes an N-terminal methionine, and is hereafter named
bovine met-β2m.
Radiolabeling of human and bovine met-β2m
Recombinant human β2m and bovine met-β2m were
radiolabeled with iodine (125I) using the chloramine-T proce-
dure (Hunter and Greenwood 1962). Twenty microgramsβ2m
was mixed with 1 mCi 125I (Perkin-Elmer, NEZ033A005MC)
and 5 μl (1 mg/ml) chloramine-T (Sigma C9887) in a total
volume of 65 μl. The reaction was stopped after 1 min by the
addition of 5 μl metabisulfite (1 mg/ml). Free iodine was
removed by size exclusion chromatography using a 1 ml
Sephadex G10 column equilibrated in PBS/2% ethanol/
0.1 % azide. The column was eluted with PBS/2 % ethanol/
0.1 % azide and 200 μl fractions were collected. Column
fractions were tested for gamma emission and labeled frac-
tions were pooled. Radiolabeledβ2mwas stored at 4 °C for no
more than 4 weeks.
Bovine peptide-binding motifs by scintillation proximity
assay
A nonameric peptide-binding motif was determined for 8
recombinant bovine MHC proteins: BoLA-6*01301
(HD6), -2*01201 (T2A), -6*04101 (T2B), -T2C, -
3*00101 (AW10), -3*00201 (JSP.1), -1*02301 (D18.4)
and -T7. Here, the names in parenthesis (i.e., HD6) are
the “old” allele names often used in the literature, and the
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BoLA names are from the IPD (Robinson et al. 2013).
Three sequences are not available in the IPD. These are
available from Genbank with the following GI’s; T2C
−158516741, T5 −158516743, and T7 −158516745. The
different MHC proteins are found in the following breed of
cattle (data obtained from the IPD and Genbank): Holstein
(BoLA-6*01301 (HD6), BoLA-2*01201 (T2A), BoLA-
3*00201 (JSP.1), and BoLA-1*02301 (D18.4)), Boran
(BoLA-3*00101 (AW10)), Jersey (BoLA-6*04101
(T2B)), Bos taurus×Bos indicus (BoLA-T2C and BoLA-
T7), and Bos indicus (BoLA-T5). The nonameric PSCPL
library (Stryhn et al. 1996) was evaluated in a recently
developed MHC Class I peptide dissociation assay based
on a scintillation proximity assay principle (SPA)
(Harndahl et al. 2011). The recombinant bovine MHC-I
proteins stored in 8 M urea was diluted at least 100 fold in
a PBS/0.1 % Lutrol F68 buffer containing peptide and 125I
radiolabeled recombinant bovine met-β2m to initiate
pMHC complex formation. The reactions were carried
out in streptavidin-coated scintillation 384-well HTS
F l a s h p l a t e® P l u s m i c r o p l a t e s ( P e r k i n -E lme r
SMP410A001PK). The final concentration of the MHC-I
heavy chain was between 12.5–100 nM depending on the
specific activity of each protein. The mixture containing
the recombinant bovine heavy chain, radiolabeled bovine
met-β2m and the peptide mix with a specific amino acid in
a given position was incubated overnight at 18 °C. After
incubation, an excess amount (200 nM) of unlabeled bo-
vine met-β2m was added to prevent re-association of dis-
sociated complexes and the dissociation was initiated by
transferring the plate to 37 °C. The plates were read con-
tinuously for 24 h at 37 °C in a Perkin-Elmer Topcount
NXT Liquid Scintillation Counter.
Analysis of PSCPL data
The area under the dissociation curve (AUC) was calculated
after background subtraction by summarizing the CPM from
0–24 h. The relative binding (RB), i.e., the relative contribu-
tion of each residue in the sub-library to peptide binding was
calculated according to the equation:
Relativebinding;RB ¼ AUCsublibrary
AUCX9
AUC is the area under the dissociation curve from 0 to
24 h. The RB values of each amino acid in a given position
were summarized and normalized so the sum equals 20. The
anchor position (AP) values for a given position, defining the
relative contribution of this position to peptide binding, were
calculated as:
AP ¼ Σ 1−RBsublibrary
 2
Generation of sequence logos
Sequence logos describing the amino acid binding specificity
captured by the PSCPL were calculated using the Seq2Logo
sequence logo generator (Thomsen and Nielsen 2012). In
short, the RB values at each peptide position were normalized
by the sum of the RB values at the given position. This
normalized PSCPL matrix was submitted to the Seq2Logo
server, and binding motif visualized as a p-weighted
Kullback-Leibler logo generated using a flat amino acid back-
ground distribution (i.e. all amino acids are assumed to be
found with an equal frequency). In this type of logo, a tall
stack of letters characterizes anchor positions and amino acids
presented on the positive y-axis are enriched in peptide
binders and amino acids on the negative y-axis are depleted
from peptide binders.
Stability of recombinant bovine pMHC complexes
The stability of the recombinant pBoLA-I complexes was
determined using the aforementioned SPA-based peptide–
MHC Class I dissociation assay (Harndahl et al. 2011).
Bovine class I peptide-binding assay
Peptide affinity to bovine MHC-I molecules was determined
using a peptide–MHC-I binding assay where pMHC-I com-
plexes are detected via the luminescent oxygen channeling
immunoassay (LOCI) principle (Harndahl et al. 2009).
Briefly, lyophilized peptides were dissolved in PBS/0.1 %
Lutrol F68 by sonication for 10 min. Five-fold dilution series
of peptides were done in 384 well microplates using a
Microlab® STAR liquid handling robot (Hamilton
Robotics). Recombinant, denatured bovine heavy chains were
diluted into PBS/0.1 % Lutrol® F 68/100 mM Tris/maleate
(pH 6.6) containing pre-folded recombinant human β2m on
ice. The HC/β2m mixture was added 1:1 to the peptide titra-
tions and incubated for 48 h at 18 °C to ensure proper MHC-I
complex folding. The final concentration of bovine heavy
chain ranged from 0.5 to 10 nM and β2m concentrations
ranged from 5 to 25 nM based on the optimal signal to
background ratio for the specific protein obtained from dose-
response experiments. Following complex folding, samples
were transferred to 384 well Optiplates™ and mAb W6/32
conjugated acceptor beads and streptavidin coated donor
beads (Perkin Elmer, 6762001 conjugated in-house with
mAb W6/32 and 6760002) were added, giving a final bead
concentration of 15 μg/ml of each. Plates were incubated
overnight at 18 °C to obtain equilibrium and subsequently
read in an Envision® multi label reader (Perkin Elmer) after
equilibration to room temperature. All handling of LOCI
reagents was done in dark or in green light. All data handling
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and non-linear regression was done using Microsoft® Office
Excel® and GraphPad® Prism.
Binding affinity of recombinant human β2m and bovine
met-β2m to BoLA-6*01301 (HD6)
The binding affinity of human β2m and bovine met-β2m to
BoLA-6*01301 was measured in a competitive binding assay.
In a 96-well HTS Flashplate® Plus microplate, a fixed con-
centration of 125I labeled bovine met-β2m, biotinylated BoLA
6*01301 (50 nM) and a binding peptide was incubated in the
presence of increasing concentrations of unlabeled human
β2m or bovine met-β2m (0.45 nM to 1 μM) for 24 h at
18 °C to allow pMHC-I complex folding. A parallel experi-
ment was done using 125I labeled bovine. Plates were read in
Perkin-Elmer Topcount NXT Liquid Scintillation Counter.
Data was analyzed using Graphpad® Prism and IC50 values
calculated using “Log agonist versus Inhibitor” model.
Peptide-binding specificity of BoLA 6*01301 (HD6) using
recombinant bovine or human β2m
The peptide-binding specificity of BoLA-6*01301 was
assessed using SPA driven PSCPL analysis (position 2 and 9
only) as described above using either 125I radiolabeled human
β2m or bovine met-β2m. Dissociation was initiated by addi-
tion of excess of unlabeled β2m of the relevant species.
Results
Generation of BoLA-I molecules
We have previously generated recombinant MHC proteins
from different species such as human, swine and others
(Ferre et al. 2003; Ostergaard Pedersen et al. 2001; Pedersen
et al. 2011). Here, we transfer the underlying approaches to the
BoLA system. The focus of this study has been on the bovine
alleles BoLA-6*01301 (HD6), BoLA-2*01201 (T2A),
BoLA-6*04101 (T2B), BoLA-T2C, BoLA-3*00101
(AW10), BoLA-3*00201 (JSP.1), BoLA-1*02301 (D18.4),
and BoLA-T7.
The recombinant biotinylated bovine MHC proteins
were expressed and purified as described in “Materials
and methods”. As seen by non-reducing SDS-PAGE anal-
ysis (Fig. 1a), we were able to isolate denatured, recombi-
nant bovine MHC-I molecules of high purity. The degree
of biotinylation was assessed in a biotin-avidin gel-shift
assay and ranged between 90 and 100 % (Fig. 1a), thus
providing fully biotinylated, recombinant BoLA-I mole-
cules for biochemical assays.
Generation of BoLA met-β2m
Bovine met-β2m was likewise produced as described in the
“Materials and methods” section. Following refolding, the
protein was purified by size exclusion chromatography,
resulting in a highly pure protein preparation (Fig. 1b).
Generation of peptide–BoLA-I binding and stability assays
We have reported two assays that enable high-throughput
measurement of the stability of the pMHC-I complex (half-
life, t1/2) and the peptide–MHC-I (pMHC-I) binding affinity,
respectively (Harndahl et al. 2009, 2011). The former is based
on the dissociation of radiolabeled β2m from pMHC-I com-
plexes as an indirect measure of peptide dissociation, first
shown by Parker et al. (1992), here modified to allow detec-
tion in a high-throughput setting via the SPA principle. The
latter is based on detection of pMHC-I complexes from ligand
saturation experiments via the luminescent oxygen channeling
immunoassay principle (LOCI). Our aim was to use these two
assays to measure the affinity and stability of pMHC com-
plexes from bovine species. The LOCI-based assay depends
on the mAb W6/32 epitope, that only recognizes folded
pMHC-I complexes, while the dissociation assay is dependent
on successful radiolabeling of β2m. As proof of concept, the
immunodominant epitope VGYPKVKEEML restricted by
the BoLA-6*01301 (HD6) allotype (Macdonald et al. 2010)
was tested in the two assays. The VGYPKVKEEML-BoLA-
6*01301 (HD6) complex dissociated at a rate that resembled
rates observed for human epitopes (Harndahl et al. 2012)
(t1/2=10.2 h, Fig. 2a). This shows that both the recombinant
BoLA-I heavy chain and bovine met-β2m are functional and
capable of forming stable pMHC-I complexes. Next, we test-
ed whether the pBoLA-I complexes could be detected by the
W6/32 monoclonal antibody in the LOCI assay. Dose-
response titrations of recombinant BoLA-6*01301 (HD6)
and bovine met-β2m in the presence and absence of the
VGYPKVKEEML peptide yielded no peptide specific signal
(data not shown). It has been reported that N-terminus of β2m
is involved in the formation of theW6/32 epitope (Shields and
Ribaudo 1998) and in the case presented here, the N-terminal
methionine of the recombinant bovine met-β2m likely inter-
feres with W6/32 detection. Alternatively, the failed W6/32
recognition may be explained by the lack of pan-specificity of
the antibody to BoLA-I when associated with bovine
met-β2m (Joosten et al. 1992). Substituting bovine met-β2m
with human β2m, lacking the N-terminal methionine, howev-
er, proved highly suitable for theW6/32 based LOCI detection
with BoLA-6*01301. As shown in Fig. 2b, human β2m
support BoLA-I folding and W6/32 epitope formation and
the binding affinity of the VGYPKVKEEML epitope to
BoLA-6*01301 (HD6) was determined to 2.7 nM.
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We next assessed whether the use of human β2m in BoLA-
I binding experiments affected the peptide-binding specificity
of BoLA-I allotypes. To investigate this, we measured the
binding affinity of human β2m versus bovine met-β2m to
bovine MHC-I in a competitive binding assay. BoLA-
6*01301 (HD6) and a binding peptide (VGYPKVKEEML)
were incubated with either radiolabeled human β2m or bovine
met-β2m and unlabeled human β2m or bovine met-β2m. The
binding affinity of the bovine met-β2m to the recombinant
bovine MHC-I heavy chain BoLA-6*01301 (HD6) was de-
termined to be 6.7 nM while the affinity of the recombinant
human β2m to BoLA-6*01301 (HD6) was 2.5 nM (data not
shown). This suggests a very limited effect on the binding
affinity of replacing bovine met-β2m with human β2m.
We next investigated if the use of human β2m altered the
specificity of the bovine class I peptide-binding groove. Using
a nonameric positional scanning combinatorial peptide library
(PSCPL) in combination with a scintillation proximity assay
(SPA)-based pMHC-I dissociation assay, we analyzed the
specificity of peptide positions 2 and 9 in BoLA-6*01301
(HD6) with both radiolabeled human β2m and bovine
met-β2m. We observed very limited change in the specificity
of these two key positions (see Supplementary file 1). From
these results, we concluded that the use of human β2m is a
valid substitution for bovine β2m in pBoLA-I binding assays,
and for the remainder of this study used recombinant human
β2m for LOCI based peptide-binding experiments for all
recombinant bovine heavy chains.
Fig. 1 Purification and in vivo biotinylation of recombinant bovine
MHC molecules. Recombinant bovine MHC-I alpha chains were
expressed in E. coli BL21(DE3) and inclusion bodies were isolated,
dissolved and purified under denaturing conditions. In vivo biotinylation,
via co-expression of BirA, was assessed in the purified protein product,
shown here for BoLA-T2c (a), by a SDS-PAGE gel-shift assay where the
biotinylated protein is incubated with increasing concentrations of avidin
prior to SDS-PAGE analysis. Bovine met-β2m was expressed in E. coli
BL21(DE3) and resulting inclusion bodies were isolated, dissolved in
denaturing buffer, purified by ion-exchange chromatography and the
protein refolded. After refolding the protein was purified size exclusion
chromatography (b) resulting in a highly pure protein product, here
visualized by non-reducing SDS-PAGE analysis of SEC peak fractions






















Fig. 2 Development of BoLA-I ligand binding assays. Left panel Dis-
sociation kinetics of the VGYPKVKEEML-BoLA-6*01301 (HD6) com-
plex. Radiolabeled pBoLA-I complexes were formed by overnight incu-
bation of recombinant, denatured, and biotinylated BoLA-6*01301
(HD6) with 125I-radiolabeled bovine met-β2m and excess of peptide.
After addition of excess of unlabeled bovine met-β2m, the pBoLA-I
complex decay was monitored continuously for 24 h. Right panel Bind-
ing of the immune dominant epitope VGYPKVKEEML to the restricting
BoLA-6*01301(HD6) allotype. Peptide-BoLA-I complexes were gener-
ated by incubation of recombinant, denatured, and biotinylated BoLA-
6*01301 (HD6)with excess of humanβ2m and increasing concentrations
of peptide. pBoLA-I complexes were detected by luminescent oxygen
channeling immunoassay (LOCI) via streptavidin conjugated donor
beads and W6/32 conjugated acceptor beads, ensuring detection of cor-
rectly folded pBoLA-I complex only
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Determining MHC-I peptide-binding motifs by positional
scanning combinatorial peptide libraries
We used the approach described earlier (paper submitted for
publication), combining the dissociation assay and the
Positional Scanning Combinatorial Peptide Library
(PSCPL), to characterize the peptide-binding motifs of eight
BoLA-I molecules. A prerequisite to a PSCPL analysis is that
a given recombinant MHC protein can bind the reference X9
peptide library, and thereby generate a specific signal com-
pared to a negative control without peptide. Figure 3 shows an
example of BoLA-6*01301 (HD6) bound to three different
sub-libraries; XXXXXXXXX (X9), XXXXXXXXL (X8L)
and XXXXXXXXN (X8N). A large increase in binding and
stability of the X8L library compared to X9, and a large
decrease for the X8N library is seen, showing that leucine
(L) is a highly favored and asparagine (N) a highly disfavored
amino acid at the ninth position of a nonameric peptide. The
ratio between the area under the dissociation curve (AUC) of a
sub-library and the AUC of the reference library X9 is the
relative binding (RB). RB values below 0.5 are considered as
disfavored for binding, values 0.5<RB<2 are accepted and
residues with values above 2 are considered favored for
binding.
Measurement of the pMHC-I complex stability of all 180
nonameric sub-libraries of the PSCPL can be summarized as a
detailed binding matrix, which identifies favored and
disfavored amino acid residues for each amino acid position.
The PSCPL-derived binding matrices represent BoLA-I bind-
ing motifs and can be shown as position specific weight
matrices of RB values or visualized as logos using the
Seq2Logo web-server (Thomsen and Nielsen 2012). An ex-
ample of a PSCPL derived peptide-binding motif is shown in
Fig. 4 for the molecule BoLA-6*01301 (HD6). This molecule
was found to have a well-defined peptide-binding motif
characterized by two anchor positions: one anchor at the C-
terminal (P9) with preference for hydrophobic amino acids
and one anchor at P2 with preference for neutral (Q) and
hydrophobic (M, L) amino acids. The C-terminal and P2
anchor positions is in agreement with the motif suggested
earlier obtained using alanine scan (Macdonald et al. 2010).
Of note is that Macdonald et al. showed that for the given
peptide analyzed in their study, P5 had greater involvement
than the P2 residue in MHC binding. This observation is not
reproduced in our findings.
Using this SPA-based PSCPL analysis, we were able to
characterize the binding motif of 8 of the 9 recombinant
BoLA-I allotypes produced (BoLA-6*01301 (HD6), BoLA-
2*01201 (T2A), BoLA-6*04101 (T2B), BoLA-T2C, BoLA-
3*00101 (AW10), BoLA-3*00201 (JSP.1), BoLA-1*02301
(D18.4), and BoLA-T7). For the BoLA-T5 molecule, we were
unable to obtain a peptide-specific signal in the SPA driven
pMHC-I dissociation hindering PSCPL analysis, and this
molecule was not analyzed further. A sequence logo represen-
tation of the binding motifs is shown in Fig. 5 (the individual
weight matrices are shown in Supplementary file 2). All
BoLA-I proteins except BoLA-2*01201 (T2A) showed a
strong preference for amino acids with hydrophobic properties
at the C-terminal position of the peptide; in particular favoring
the amino acids F, I, L, and M. The F pocket of the MHC-I
proteins is formed by the following polymorphic residues 74,
77, 80, 81, 84, 95, 97, 116, 118, 143, and 147 of the MHC-I
alpha chain (Nielsen et al. 2007). Of these, positions 77, 80,
81, and 116 are considered key residues (Sidney et al. 2008).
Figure 6 shows the amino acids forming the F pocket of the
different MHC proteins. It appears that the majority of the
pocket residues belong to functional groups that favor inter-
actions with hydrophobic residues. One outlier in the pocket
analysis is BoLA-2*01201 (T2A). This molecule has a strong
C-terminal preference for positively charged residues arginine
and lysine (see Fig. 5). A similar C-terminal preference is
observed for the human HLA-A*03:01 molecule (McMahon
et al. 2011). Comparing the residues lining the F pocket of the
HLA-A*03:01 molecule with the BoLA molecules offers a
potential explanation of the observed binding motifs prefer-
ences. In contrast to the other BoLA molecules, both the
BoLA-2*01201 (T2A) and the HLA-A*03:01molecules have
a D in positions 77 and 116, resulting in an acidic C-terminal
pocket suggesting that these amino acids are critical in deter-
mining the F pocket preference for basic amino acids.
Biochemical characterization of known BoLA-I restricted
epitopes
A small set of known T. parva CD8 restricted epitopes re-
stricted by the BoLA-I molecules included in this study has
been reported (Graham et al. 2008). To further validate the
functionality of the peptide-binding and stability assays









Fig. 3 Positional Scanning Combinatorial Peptide Library (PSCPL)
analysis of the binding specificity of BoLA 6*01301 (HD6) measured
by pMHC-I dissociation. The pBoLA-I dissociation curves are shown for
two sub-libraries (X8L and X8N) and the reference library (X9). The
relative binding (RB) values are calculated for the dissociation data as
the ratio of the area under the dissociation curve (AUC) of the sub-library
and the AUC for the reference library (X9)
Immunogenetics
described here, we measured the binding affinity and stability
of nine T. parva epitopes with their cognate BoLA-I mole-
cules using the LOCI based binding assay to determine the
equilibrium dissociation constant (binding affinity, KD in nM)
and the SPA-based dissociation assay to determine the stabil-
ity of the pMHC complexes (half-life, t1/2 in hours).
The results, shown in Table 1 confirm that the epitope
sequences form high affinity, stable complexes with the cor-
responding BoLA-I restriction element. For example, the
BoLA-6*01301 (HD6) res t r ic ted 11mer epi tope
VGYPKVKEEML was found to have an affinity of 2.7 nM
and a half-life (t1/2) of 11 h. The BoLA-6*04101 (T2B)
restricted epitope SHEELKKLGML, however, could not be
detected in the stability assay, and the affinity was determined
to be 4,558 nM. This strongly suggested that this peptide
sequence is not a minimal epitope, and that the epitope is
nested within this sequence. This has been recently confirmed
(Svitek et al. 2014).
Cross reactivity of known BoLA-I restricted epitopes
In order to investigate the cross reactivity between epitopes
and MHC molecules, we measured the binding affinity and
complex stability of the 9 T. parva epitopes described
above and the T5 epitope SKADVIAKY to the eight
BoLA-I molecules. Note, the original T5 restriction of
SKADVIAKY was not measured, as we were not able to
develop functional assays for this molecule. The result of
Fig. 4 PSCPL derived peptide-binding motif of BoLA-6*01301 (HD6).
Left panel Peptide-binding matrix obtained by peptide–MHC-I dissocia-
tion assay based PSCPL analysis. Relative binding values >2 are consid-
ered favored amino acids, values 0.5–1.5 are considered tolerated and
values below 0.5 are considered disfavored. AP values >10 are
considered anchor positions. Right panel Sequence logo representation
of the binding motif. The sequence logo was generated using the
Seq2Logo server (Thomsen and Nielsen 2012) as described in the text.
Hydrophobic amino acids F, I, L, andM are favored at the anchor position









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 5 Sequence logo representation of the binding motif of the 8 BoLA-I molecules. Logos were generated using the Seq2Logo server (Thomsen and
Nielsen 2012) as described in the text
Immunogenetics
this analysis is shown in Table 1. Only a limited degree of
cross binding was observed between the different mole-
cules. One striking example of cross binding is the sug-
gested restriction of VGYPKVKEEML to BoLA-6*04101
(T2B) with an affinity of 12 nM and a half-life time of
12 h. BoLA-6*01301 (HD6) and BoLA-6*04101 (T2B)
are very similar in sequence, and only five amino acids
differ between the two full protein sequence with four of
these forming part of the pseudo sequence lining the MHC
binding cleft (Nielsen et al. 2007). Further, the BoLA-T2C
restricted epitope FAQSLVCVL and the BoLA-3*00101
(AW10) restricted epitope TGASIQTTL were both found
to cross-bind to BoLA-3*00201 (JSP.1) and the BoLA-T5
restricted epitope SKADVIAKY was found to bind with an
affinity of 15 nM and a stability of 18 h to BoLA-1*02301
(D18.4). The latter observation confirms what has been
reported earlier (MacHugh et al. 2011; Svitek et al. 2014).
Testing discrete peptides
The PSCPL-driven analysis is ideally suited to give a first
representation of the peptide-binding motif. However, it is not
well suited to capture correlated effects where an amino acid
in one position may affect the specificity of another position.
The latter is most efficiently captured when investigating the
binding of a large number of discrete peptides. Approximately
90 discrete high-scoring peptides for each BoLA-I molecule
were selected from our peptide repository containing more
than 9,000 distinct nonamer peptides according to each of the
PSCPL matrices described above multiplying the relative
binding (RB) values for each amino acid in each position.
To complement this PSCPL matrix-driven selection, an addi-
tional set of 90 discrete peptides was selected for each MHC
molecule with high-predicted binding affinity according to the
NetMHCpan prediction method but low predicted affinity
Fig. 6 Amino acids forming the
F pocket of the different BoLA-I
proteins and the human allo-
morph HLA-A*03:01. The fol-
lowing color scheme was used:
green small non-polar amino
acids, gray hydrophobic amino
acids, red negative charged amino
acids, orange polar. F pocket
contact residues were identified as
described in (Nielsen et al. 2007).
Numbers in the first row corre-
spond to residue positions in the
mature MHC protein sequence
(according to the IMGT
nomenclature)
Table 1 Peptide–BoLA-I binding affinity and complex stability of known T. parva CTL epitopes




















Tp1214–224 VGYPKVKEEML HD6 (6*01301) 3 11 T2B (6*04101) 12 14
Tp227–37 SHEELKKLGML T2B (6*04101) 4558 Not detectable
Tp249–59 KSSHGMGKVGK T2A (2*01201) 364 2
Tp296–104 FAQSLVCVL T2C 144 57 JSP.1 (3*00201) 767 4
Tp298–106 QSLVCVLMK T2A (2*01201) 18 3
Tp4328–336 TGASIQTTL AW10 (3*00101) 40 23 JSP.1 (3*00201) 564 2
Tp587–95 SKADVIAKY T5 D18.4 (1*02301) 15 18
Tp7 EFISFPISL T7 252 14
Tp 8379–387 CGAELNHFL AW10 (3*00101) 30 14 JSP.1 (3*00201) 431 2
Tp9199–228 AKFPGMKKSK D18.4 (1*02301) 100 4
The peptide-BoLA-I binding affinity (EC50) and complex stability (t1/2) of known T. parva epitopes was measured for published ((Nene et al. 2012)) and
proposed alternative restriction elements
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according to the PSCPL matrix prediction. This second selec-
tion complements the PSCPL selection by choosing peptides
that do not fit the motif captured by the PSCPL but are
predicted to bind by the NetMHCpan method (Hoof et al.
2009; Nielsen et al. 2007) as trained without prior explicit
knowledge about the specificity of the given BoLA-I mole-
cule.We have earlier demonstrated that such a complementary
selection strategy is a highly cost-effective approach, which
allows the identification of individual peptides highly
enriched in MHC binders and rich in information critical for
the subsequent training of improved algorithms (paper sub-
mitted for publication).
Each peptide within these data sets was next assayed for
binding affinity to the respective BoLA-I molecules using the
LOCI based pMHC-I binding assay. The results of these
screenings are summarized in Table 2. Several observations
can be made from the data presented in Table 2. First of all, it
is clear that the PSCPL matrices in most cases have a very
high predictive capacity for identification of binders to the
BoLA-I molecules. Only one molecule, BoLA-3*00101
(AW10), had a very low performance with only 9 % of the
selected peptides being binders. For the remaining seven
molecules on average 55% [26–93%] of the selected peptides
were found to bind the respective molecule (KD<500 nM). A
second important observation is that the NetMHCpan selected
peptides also to some degree [9–70 %, excluding BoLA-
3*00101 (AW10)] bound the respective BoLA-I molecules.
This is somewhat surprising since the NetMHCpan peptides
were explicitly selected to not match the binding motif de-
scribed by the PSCPL’s. These observations thus suggest that
the PSCPL matrix approach in general only captures a subset
of the overall binding specificity of an MHC molecule, and
that the characterization of the specificity can be effectively
complemented using predictions of the NetMHCpan method.
That the two approaches are complementary is further
underlined by the fact that only between 20 and 60 % of the
identified BoLA binding peptides would have been predicted
using the NetMHCpan method trained without any prior
knowledge about the specificity of the BoLA molecules (data
not shown).
In silico validation of known BoLA-I epitopes
The discrete peptide-binding affinity data were next used to
retrain the NetMHCpan and NetMHC methods. The updated
versions are available at www.cbs.dtu.dk/services/
NetMHCpan and www.cbs.dtu.dk/services/NetMHC. Using
the updated prediction methods, we next used a set of
BoLA-I epitopes earlier described in the literature
(MacHugh et al. 2011; Nene et al. 2012) to investigate to what
degree a consensus method defined as a simple average of the
NetMHCpan and NetMHC prediction values was able to
predict the suggested restrictions. The analysis was performed
as described previously (Nene et al. 2012). In short, for each
epitope, the evaluation was made by predicting the binding
affinity for all 8 to 11mer peptides contained within the source
protein, and next calculating the fraction of peptides with a
predicted binding affinity stronger than the predicted binding
affinity of the known CTL epitope (the false-positive predic-
tion rate, FR). In situations where the BoLA-I molecule was
not covered by the NetMHC method, only the NetMHCpan
predictions were used. The result of this analysis is shown in
Table 3.
Several important conclusions can be drawn from the anal-
ysis. First and foremost, it is evident that the NetMHC
consensus method in the majority of cases was able to accu-
rately identify the known BoLA-I epitope within the given
source protein sequence. However, in some cases, the epitope
sequence obtained from the literature matched the predicted
binding motif of the restricting BoLA-I molecule very poorly,
as seen with the T. parva epitopes SHEELKKLGML and
EFISFPISL restricted to BoLA-2*01201 (T2A) and BoLA-
T7, respectively. These peptides are predicted with false-
positive rates of 2 and 6.5 % having 14 and 184, alternative
peptides, respectively, with a stronger predicted binding affin-
ity value than the reported epitope within the source protein
sequence. In contrast to this, the alternative nested peptides
EELKKLGML and FISFPISL have very low false-positive
rates (0 and 0.1 %). A similar argument can be made for most
other epitopes with a FR above 2.5 %. In all these cases, an
optimal epitope nested within the original epitope can be
identified with corresponding FR values close to or even equal
to 0. Only one epitope, the Tp9 epitope AKFPGMKKSK
restricted to BoLA-1*02301 (D18.4), remains poorly de-
scribed following these arguments. This epitope is predicted
with a false position rate of 5 %, and no nested alternative
peptides are found with a lower FR value.
To investigate further if the suggested alternative epitopes
were indeed stronger binders compared to the original epi-
topes, we measured binding affinity values of six of the eight
peptides from Table 3 where the in silico predictions sug-
gested alternative truncated optimal minimal epitopes. In all
cases, the experimental validations confirmed a stronger bind-
ing affinity for the suggested alternative minimal epitopes (see
Table 4).
Discussion
In this work, we have presented a strategy to analyze the
peptide-binding motif of recombinant MHC-I proteins from
cattle by measurement of the peptide–MHC-I complex stabil-
ity of positional scanning combinatorial peptide libraries in a
scintillation proximity assay (Harndahl et al. 2011). Our work
demonstrates that the strategy published earlier for the human
Immunogenetics
Table 2 Peptide binding to BoLA-I molecules
MHC allotype N KD<50 nM 50 nM<KD<500 nM 500 nM<KD<5000 nM KD>5000 nM
PSCPL selected peptides
3*00101 (AW10) 83 1 (1 %) 7 (8 %) 18 (22 %) 57 (69 %)
1*02301 (D18.4) 83 8 (10 %) 42 (51 %) 12 (14 %) 21 (25 %)
6*01301 (HD6) 87 50 (57 %) 27 (31 %) 6 (7 %) 3 (3 %)
3*00201 (JSP.1) 84 6 (7 %) 16 (19 %) 18 (21 %) 44 (52 %)
2*01201 (T2A) 80 0 (0 %) 39 (49 %) 35 (44 %) 6 (8 %)
6*04101 (T2B) 84 10 (12 %) 17 (20 %) 14 (17 %) 43 (51 %)
T2C 90 65 (72 %) 19 (21 %) 4 (4 %) 2 (2 %)
T7 83 0 (0 %) 29 (35 %) 37 (45 %) 17 (20 %)
NetMHCpan selected peptides (not matching PSCPL)
3*00101 (AW10) 84 0 (0 %) 0 (0 %) 1 (1 %) 83 (99 %)
1*02301 (D18.4) 84 5 (6 %) 54 (64 %) 15 (18 %) 10 (12 %)
6*01301 (HD6) 85 12 (14 %) 39 (46 %) 29 (34 %) 4 (5 %)
3*00201 (JSP.1) 74 1 (1 %) 9 (12 %) 22 (30 %) 42 (57 %)
2*01201 (T2A) 87 0 (0 %) 8 (9 %) 33 (38 %) 46 (53 %)
6*04101 (T2B) 73 0 (0 %) 11 (15 %) 22 (30 %) 40 (55 %)
T2C NA NA NA NA NA
T7 66 2 (3 %) 8 (12 %) 32 (48 %) 24 (36 %)
Peptide binding to BoLA-I molecules was measured for two sets of peptides; one consisting of peptides predicted to bind according the PSCPL derived
bindingmotif (upper half) and one set of peptides predicted to bind according to theNetMHCpan predictionmethod but not by the PSCPL bindingmotif
Table 3 In silico prediction of known T. parva and T. annulata CTL epitopes
Pathogen Epitope BoLA Protein #pep #FP FR Alternative FR
T. parva VGYPKVKEEML 6*01301 (HD6) Tp1 2138 34 0.016
SHEELKKLGML 6*04101 (T2B) Tp2 662 14 0.021 EELKKLGML 0.000
DGFDRDALF 6*04101 (T2B) Tp2 662 143 0.216 GFDRDALF 0.041
KSSHGMGKVGK 2*01201 (T2A) Tp2 662 3 0.005
FAQSLVCVL T2C Tp2 662 15 0.023
QSLVCVLMK 2*01201 (T2A) Tp2 662 5 0.008
KTSIPNPCKW 2*01201 (T2A) Tp2 662 91 0.137 KTSIPNPCK 0.015
TGASIQTTL 3*00101 (AW10) Tp4 2282 7 0.003
SKADVIAKY T5 Tp5 586 2 0.005
EFISFPISL T7 Tp7 2850 184 0.065 FISFPISL 0.001
CGAELNHFL 3*00101 (AW10) Tp8 1726 12 0.007
AKFPGMKKSK 1*02301 (D18.4) Tp9 1302 68 0.052
Ave 0.046 0.015
T. annulata SKADVIAKY 1:02301 Ta5 586 4 0.007
QRSPMFEGTL 3:00201 Ta9 1306 15 0.011 RSPMFEGTL 0.000
ERSPTFGGPLa 3:00201 Ta9 1306 36 0.028 RSPTFGGPL 0.000
SKFPKMRMG 1:02301 Ta9 1306 96 0.074 SKFPKMRM 0.007
KRKTEGYVF 2:02201 Ta11 1630 23 0.014
Ave 0.027 0.006
The columns are: Epitope the CTL epitope sequence from the literature;MHC the corresponding restriction element; Protein the source protein ID; #pep
the number of unique 8–11mer peptides contained within the source protein; #FP the number of false-positive predictions (peptides with a predicted
binding affinity value stronger than the known epitope); FR the false-positive ratio (#FP/#pep); Alternative the predicted alternative epitope, and FR the
false-positive ratio for the alternative epitope. If no alternative epitope was predicted, the last column is left empty. (Ave) gives the average value for the
peptide subset. Data from (Nene et al. 2012) and (MacHugh et al. 2011)
a Allelic variant of QRSPMFEGTL (Ivan Morrison, personal communication)
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HLA system can be implemented in the analysis of MHCs
from other species such as cattle.
By assaying a positional scanning combinatorial peptide
library (PSCPL) in a high-throughput scintillation proximity
dissociation assay, we obtained peptide-binding motifs of
eight recombinant bovine MHC’s, all showing a dominant
anchor at the C terminus of the peptide. The anchor in the
amino terminal end of the peptide was at P2 in most cases,
with some peptides having additional anchors at positions 1,
3, 5, or 6.
We confirmed these data by analyzing the binding proper-
ties of 9 published epitopes from T. parva to the proposed
restricting MHC allotypes and eight of these were found to
bind and form stable complexes with restricting BoLA-I mol-
ecule. We could not detect binding of the BoLA-6*04101
(T2B) restricted SHEELKKLGML epitope in the dissociation
assay and the affinity was measured to be 4,558 nM, which
makes it an unlikely epitope. In contrast, the nested peptide
EELKKLGML bound with high affinity and stability to
BoLA-6*04101, suggesting that this truncated peptide could
be the minimal epitope. This has recently been experimentally
confirmed by comparing the fraction of T cells stained by
tetramers formed with the two peptide sequences (Svitek
et al. 2014). When expanding the analysis to other BoLA-I
restricted CTL epitopes, similar arguments could be put for-
ward in cases of weak predicted binding affinity. In all cases,
the alternative epitopes were predicted to be nested within a
longer peptide, and in all cases the alternative epitope was
found to have improved binding to the corresponding BoLA-I
restriction element. These findings strongly suggest that, in
such cases, the optimal epitope is nested within the previously
defined epitope. Therefore, the above findings suggest that the
identification of the original epitopes, in most cases performed
using IFN-γ ELISpot assays (Graham et al. 2008), was de-
pendent on the additional amino acids flanking the minimal
epitope being trimmed off by peptidases prior to binding to
BoLA-I. The actual epitope is defined by the nested peptide
that has improved binding affinity and stability to the BoLA-I
molecule.
Using PSCPL-derived binding motifs and the
immunoinformatics prediction method NetMHCpan, we
selected a large set of discrete peptides that were
experimentally assayed for binding to the BoLA-I mole-
cules. Incorporating these binding data in the training of
the NetMHC and NetMHCpan methods led to improved
prediction accuracy of known T. parva CTL epitopes. We
then tested the nine epitopes for cross binding to each of
the eight MHCs, and observed cross binding between a
series of MHCs; BoLA-6*04101 (T2B) and BoLA-
6*01301 (HD6), BoLA-T2C and BoLA-3*00201
(JSP.1), and BoLA-3*00101 (AW10) and BoLA-
3*00201 (JSP.1). In all cases, cross binding was found
to be consistent with predicted functional (i.e., binding
motif) similarities between the different molecules.
We have outlined a highly cost-effective procedure for
characterization of the peptide-binding motifs and functional-
ity for bovineMHC class I proteins. The direct outcome of the
procedure is a position specific scoring matrix characterizing
the MHC binding motif, and improved prediction methods
enabling reliable prediction of peptide binding to BoLA-I. The
resulting improved versions of NetMHCpan (version 2.8) and
NetMHC (version 3.4) are both publicly available. The de-
scribed procedure is not limited to the BoLAMHC molecules
described here and could readily be expandable (and has been
(Follin et al. 2013; Pedersen et al. 2011)) to other BoLA
molecules and other species of interest, given that the MHC
protein sequences are available.
In conclusion, we have demonstrated how the use of
high-throughput biochemical peptide-binding assays com-
bined with state-of-the art immunoinformatics can be ef-
fectively used to functionally characterize the binding
motif of BoLA class I molecules. This has resulted in
the enhanced performance of BoLA-I peptide-binding
prediction methods, empowering rational epitope discov-
ery and facilitating the identification and understanding of
the cellular immune responses to infection and during
vaccine trials in cattle.
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Table 4 Experimental validation of binding affinity of 5 known epitopes and the alternative minimal epitopes suggested by in silico predictions
BoLA Protein Epitope KD (nM) Alternative KD (nM)
6*04101 (T2B) Tp2 SHEELKKLGML 4,558 EELKKLGML 2
T7 Tp7 EFISFPISL 252 FISFPISL 142
BoLA-3:00201 Ta9 QRSPMFEGTL 309 RSPMFEGTL 8
BoLA-1:02301 Ta9 SKFPKMRMG 74 SKFPKMRM 40
BoLA-3:00201 Ta9 ERSPTFGGPL 799 RSPTFGGPL 5
Additional amino acids flanking the minimal epitope are underlined
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